InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,520.65
(
0.21%
)
US TECH 100
19,576.80
(
0.50%
)
Dow Jones
39,269.84
(
-0.16%
)
Brent Oil
85.99
(
-0.53%
)
Bitcoin
60,275.08
(
-2.82%
)
Post# of 252468
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119973
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 242071

Monday, 04/25/2022 10:21:57 AM

Monday, April 25, 2022 10:21:57 AM

Post# of 252468
Shionogi PR re COVID antiviral fails to mention teratogenicity!

https://www.businesswire.com/news/home/20220423005001/en

Shionogi is evidently acting like MRK did with Molnupiravir—i.e. pretending that a safety issue does not exist. In MRK’s case, the result was a product with essentially no demand because the FDA EUA restricts usage to patients “for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate” (#msg-167236732).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up